Maxipime
(cefepime)ApprovedSmall molecule
PfizerCefepime is an antibiotic used to treat bacterial infections such as pneumonia, urinary tract infections, and bloodstream infections. It works by killing bacteria that cause these infections.[2] Maxipime is currently approved and in use across 11 indications[4].[1]
Maxipime is one of 246 small molecule programs targeting Neutropenia. It is currently in Approved.
11
Indications
23
Total Trials
3
Active Trials
245
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 11 indications
Competition
Competitive Landscape
155 competitors in Pneumonia
#DrugCompanyPhaseTrials
1Maxipime
PfizerApproved
Innohep
Jazz PharmaceuticalsPreclinical
Plaquenil
Jazz PharmaceuticalsPreclinical
Prevacid
TakedaPreclinical
Acanya
PfizerPreclinical
Primaquine
SanofiPreclinical
Jakafi
IncytePreclinical
Avlosulfon
AAlmirall, S.A.
Preclinical
Zantac 150
CChattem
Preclinical
Virazole
CConrado Roberto Hoffmann Filho
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Urinary Tract Infection3 trials
Neutropenia2 trials
Antibiotics2 trials
Efficacy2 trials
13 more indications
Surgical Site Infections1 trial
Cefepime and Unictam on Preventing Post-Cesarean Surgical Site Infections
Unknown status·—·Phase 3·NCT06048692·213 enrolled
Tics1 trial
Hematologic Disease1 trial
Cesarean Section1 trial
Single Dose Cefepime Versus Cefuroxime Plus Metronidazole as a Prophylactic Antibiotic During Emergency Intrapartum Cesarean Section
Unknown status·—·Phase 2/3·NCT04009772·500 enrolled
Bacterial Pneumonia1 trial
Cancer1 trial
Stem Cell Transplant1 trial
Prospective1 trial
Peritonitis1 trial
Comparing Cefepime Versus Cefazolin Plus Ceftazidime for CAPD-associated Peritonitis
Completed·—·Phase 4·NCT02872038·154 enrolled
Acute Kidney Injury1 trial
Septic Shock1 trial
PK/PD of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock
Completed·—·Phase 3·NCT02820987·119 enrolled
Regulatory
FDA Approval Timeline[5]
Jan 18, 1996
MAXIPIME
NDA NDA050679
Aug 5, 2008
CEFEPIME IN PLASTIC CONTAINER
NDA NDA050817
May 6, 2010
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER
NDA NDA050821
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Maxipime drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for cefepime. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]